Skip to main content
Top

An enduring debate on gliomatosis cerebri

  • 06-04-2023
  • Glioma
  • Review Article
Published in:

Abstract

Gliomatosis cerebri (GC) is a unique glial tumor that extensively invades the cerebral white matter and has been recognized as an entity of neuroepithelial tumors since the first edition of the WHO classification of brain tumors in 1979. Thereafter, in the fourth edition of the WHO classification in 2007, it was clearly defined as a specific type of astrocytic tumor. However, in the WHO 2016 classification, which was based on the concept of integrated diagnosis using molecular genetics, GC was deleted as it was considered to be only one growth pattern of diffuse glioma and not a specific pathological entity. Since then, there has been criticism by many neuro-oncologists and the establishment of the GC working group at the NIH, and many activities in the world arguing that GC should not be deleted from the clinical discussion of brain tumors. In Japan, positive activities toward multicenter research on GC pathology should be performed, and molecular pathological evidence that can contribute to the WHO classification in the future should be developed. In this article, the author outlined the pathological characteristics of GC, which has been repeated changing since its conception, and also describes his opinion on GC as a neuro-oncologist.
Title
An enduring debate on gliomatosis cerebri
Author
Jiro Akimoto
Publication date
06-04-2023
Publisher
Springer Nature Singapore
Published in
Brain Tumor Pathology / Issue 2/2023
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-023-00454-9
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME